May 22, 2007 — /PRNewswire-FirstCall/ — PASADENA, CA — Jacobs Engineering Group Inc. announced today that it is providing engineering and construction services for Genentech Inc.’s new manufacturing facility to be located in Tuas, Singapore. The new facility is intended for the manufacture of bulk LUCENTIS(R) (ranibizumab injection), a treatment for wet age-related macular degeneration. Working in partnership with Bovis Lend Lease in Singapore, Jacobs will provide full engineering services, including modular design and fabrication from its Charleston, S.C., modular fabrication operations.
Officials did not disclose the contract value.
In making the announcement, Jacobs Group vice president Arlan Emmert stated, “We are pleased to support Genentech’s international manufacturing initiatives through a collaborative effort between assets in both the United States and Singapore. We are committed to providing innovative project delivery approaches to Genentech to help ensure a high-value capital investment.”
Jacobs, with over 46,000 employees and revenues exceeding $8.0 billion, provides technical, professional, and construction services globally.
For additional information contact:
Source: Jacobs Engineering Group Inc.
Web site: http://www.jacobs.com/